back to top
HomeMarketMirum Prescription drugs to Host Investor Name to Share Interim Evaluation Outcomes...

Mirum Prescription drugs to Host Investor Name to Share Interim Evaluation Outcomes from the Volixibat VANTAGE and VISTAS research on June 17, 2024 By Investing.com

-

FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Prescription drugs, Inc. (NASDAQ: MIRM) as we speak introduced that it’s going to host an investor name on Monday, June 17 at 8:30 a.m. ET to share interim evaluation outcomes from the Volixibat VANTAGE Part 2b examine in major biliary cholangitis (PBC) and the Volixibat VISTAS Part 2b examine in major sclerosing cholangitis (PSC).

Convention name particulars:

Monday June 17, 2024

8:30 a.m. ET / 5:30 a.m. PT

Dial-in:

U.S./Toll-Free: +1 833 470 1428

Worldwide: +1 404 975 4839

Passcode: 205511

You may additionally entry the decision by way of webcast by visiting the Occasions & Shows part on Mirum’s web site. A replay of this webcast might be accessible for 30 days.

About Mirum Prescription drugs (NASDAQ:), Inc.

Mirum Prescription drugs, Inc. is a biopharmaceutical firm devoted to remodeling the remedy of uncommon illnesses affecting kids and adults. Mirum has three authorized drugs: LIVMARLI ® (maralixibat) oral resolution, CHOLBAM ® (cholic acid) capsules, and CHENODAL ® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is authorized for the remedy of two uncommon liver illnesses affecting kids and adults. It’s authorized for the remedy of cholestatic pruritus in sufferers with Alagille syndrome within the U.S. (three months and older), in Europe (two months and older), and in different areas globally. It is usually authorized within the U.S. in cholestatic pruritus in PFIC sufferers 5 years of age and older. LIVMARLI has obtained constructive opinion by CHMP in Europe for the remedy of PFIC in sufferers three months of age and older. A call by the European Fee is anticipated by the third quarter of 2024. CHOLBAM is FDA-approved for the remedy of bile acid synthesis problems attributable to single enzyme deficiencies and adjunctive remedy of peroxisomal problems in sufferers who present indicators or signs or liver illness. CHENODAL has obtained medical necessity recognition by the FDA to deal with sufferers with cerebrotendinous xanthomatosis (CTX).

Mirum’s late-stage pipeline consists of two investigational remedies for debilitating liver illnesses. Volixibat, an IBAT inhibitor, is being evaluated in two probably registrational research together with the Part 2b VISTAS examine for major sclerosing cholangitis and Part 2b VANTAGE examine for major biliary cholangitis. Lastly, CHENODAL has been evaluated in a Part 3 scientific examine, RESTORE, to deal with sufferers with CTX, with constructive topline outcomes reported in 2023.

To study extra about Mirum, go to mirumpharma.com and comply with Mirum on Fb (NASDAQ:), LinkedIn, Instagram and Twitter (X).

Traders:
Andrew McKibben
ir@mirumpharma.com

Media:
Erin Murphy
media@mirumpharma.com

Supply: Mirum Prescription drugs, Inc.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

CAPTCHA


LATEST POSTS

KeyBanc maintains Sector Weight on BrightSpring Well being shares By Investing.com

On Monday, KeyBanc Capital Markets maintained its Sector Weight score on shares of BrightSpring Well being (NASDAQ: BTSG). The choice adopted the corporate's third-quarter outcomes,...

Ethereum Set For A Bullish Breakout? Professional Cites Sturdy Upside Potential | Bitcoinist.com

As Ethereum begins to indicate constructive worth motion as soon as once more, the altcoin is seeing a wave of bullish predictions from a number...

Safetyzone Korea CEO Park Gi Pyo meets Japanese actress Yuna Ogura – Blockchain Information Web site

Among the many stars who set YouTube ablaze, Yuna Ogura is difficult to miss. Japanese grownup actress Yuna Ogura has sparked a phenomenon, being invited...

Most Popular